|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Zach Fletcher explains how an experienced manufacturing partner can help therapy developers quickly identify solutions and develop manufacturing and formulation methods for use in many applications.
|
|
|
Contributor Cindy H. Dubin speaks with several innovative companies to highlight the strides they are currently making toward improving dose accuracy, integrating design safety, and accelerating time to market.
|
|
|
Jim Huang, PhD, and Shaukat Ali, PhD, describe their LNP platform as well as the latest trends in LNPs as more and more novel therapeutic modalities discovered can’t be handled by traditional microemulsions or nanoemulsions.
|
|
|
Adam Stops, PhD, says the key to the success of any drug delivery device are factors such as proven technology, low development costs, fast time-to-market, and a strong intellectual property (IP) position for the pharma company, and against this background, platform drug delivery devices have become more important than ever.
|
|
|
|
|
|
|
|
|

With over 75 years of proven experience, Aptar Pharma is the go-to drug delivery expert, from formulation to patient, for pharma customers worldwide, providing innovative drug delivery systems, components, and active material solutions across the widest range of delivery routes, including nasal, pulmonary, ophthalmic, dermal, and injectables. Aptar Pharma Services provides early-stage to commercialization support to accelerate and de-risk the development journey. With a strong focus on innovation, Aptar Digital Health is a leading provider of integrated digital health solutions to enhance patient experiences across their treatment journey. With a global manufacturing footprint of 14 manufacturing sites, Aptar Pharma provides security of supply and local support to customers. Aptar Pharma is part of AptarGroup, Inc. Click here for more.

CLICK IMAGE FOR THIS WEEK’S FEATURED VIDEO

|
|
|
|
|
|
 |
|
Bora Pharmaceuticals recently announce the opening of a new state-of-the-art facility in Taoyuan City, Taiwan. Officially opened by Bora Pharmaceuticals CEO Bobby Sheng and President of….
|
|
 |
|
George Medicines recently announced all patients have been enrolled in its Phase 3 active-controlled trial evaluating the efficacy and safety of GMRx2, the company’s….
|
|
 |
|
As an innovative system and solution provider, Gerresheimer is the global partner for the pharma and biotech industry. In collaboration with ekipa, a leading incubator for open innovation, Gerresheimer is calling on start-ups, companies, students, researchers, and….
|
|
 |
|
Kindeva Drug Delivery and H&T Presspart are partnering with Chiesi Group for the installation of a production line for dose counter (DC) and dose indicator (DI) devices. Combining the specific….
|
|
|
|
|
|
|
|
 |
|
The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing. Since these devices….
|
|
 |
|
In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.
|
|
|
|
|
|
|
|
 |
|
Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …
|
|
 |
|
Long acting injectable (LAI) formulations have been the subject of continued interest in the recent past due, in part, to their longer systemic circulation requiring less frequent dosing of drugs. Less frequent administration, as illustrated in Figure 1, make LAIs …
|
|
 |
|
What’s In This Whitepaper?
Long-acting products, such as Long-Acting Injectables (LAIs) and implantables, have gained significant traction in recent years, revolutionizing patient treatment and medication adherence. By reducing the number of doses required, long-acting products improve patient compliance and eliminate …
|
|
 |
|
Poly(lactic-co-glycolic acid) (PLGA) has emerged as a promising material for drug delivery and biomedical applications. Its exceptional biocompatibility, customizable degradation and release properties, and versatility have led to its approval by regulatory bodies like the FDA and EMA.…
|
|
 |
|
Solubility of the active pharmaceutical ingredient (API) in an oral formulation is critical for absorption from the gastrointestinal (GI) tract and the intended therapeutic effect. Ensuring that an API has the necessary solubility can be challenging for drug developers …
|
|
|
|
|
Upcoming eNewsletter Features:
August 9 – Injection Devices
August 16 – Lyophilization Manufacturing
|
|
|
|
|
|
|
|